Showing 1511-1520 of 3134 results for "".
- FDA Approves RHA® Dynamic Volume for Midface Augmentationhttps://modernaesthetics.com/news/fda-approves-rha-dynamic-volume-for-midface-augmentation/2485309/The US Food and Drug Administration (FDA) has approved RHA® Dynamic Volume from the Teoxane RHA® Collection for cheek augmentation and correction of age-related midface contour deficiencies in adults 22 and older, Revance and Teoxane announced.
- Exosome Skin Booster Plus Microneedling Shows High Satisfaction in Retrospective Reviewhttps://modernaesthetics.com/news/exosome-skin-booster-plus-microneedling-shows-high-satisfaction-in-retrospective-review/2485225/A retrospective analysis published in Plastic and Aesthetic Nursing evaluated the clinical outcomes of an exosome-containing skin booster combined with microneedling for facial rejuvenation, reporting high patient satisfaction and favorable safety findings.<
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://modernaesthetics.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- Rheologic Profiles Differ Markedly Between Cross-Linked and Non–Cross-Linked HA Fillers, Study Findshttps://modernaesthetics.com/news/rheologic-profiles-differ-markedly-between-cross-linked-and-noncross-linked-ha-fillers-study-finds/2485091/Non–cross-linked and cross-linked hyaluronic acid (HA) dermal fillers demonstrate distinct rheologic behaviors under mechanical stress, with potential implications for product selection and injection depth, according to a comparative analysis of commercially available fillers published online in
- New Simulation Study Suggests BoNT/A Restrictions May Be Overly Conservativehttps://modernaesthetics.com/news/new-simulation-study-suggests-bonta-restrictions-may-be-overly-conservative/2485067/A large-scale, simulation-based study challenges the long-standing 4-hour restriction on post-injection activity following botulinum neurotoxin A (BoNT/A) treatment, suggesting that everyday behaviors may have minimal impact on toxin spread. The study, published in Scientific Reports, em
- New Anatomical Model Enhances Understanding of Eyelid Dynamics in Blepharoplastyhttps://modernaesthetics.com/news/new-anatomical-model-enhances-understanding-of-eyelid-dynamics-in-blepharoplasty/2485032/A recent anatomic investigation offers new insight into the biomechanical dynamics of upper eyelid movement, with potential implications for optimizing blepharoplasty outcomes and improving complication management. The study, published in Aesthetic Plastic Surgery, combines clinical, cad
- FDA Clears Cutera truFlex® for Muscle Rehab, Recovery, and Post-Surgical Usehttps://modernaesthetics.com/news/fda-clears-cutera-truflex-for-muscle-rehab-recovery-and-post-surgical-use/2485023/Cutera, Inc. has announced that its truFlex® muscle stimulation system has received expanded US Food and Drug Administration (FDA) clearances for use in rehabilitation, recovery, and muscle wellness applications. Originally cleared for aesthetic body contouring, the system can now be used to stre
- Modern Aesthetics: Enhanced Content in a New Digital Formathttps://modernaesthetics.com/news/modern-aesthetics-enhanced-content-in-a-new-digital-format/2484800/Modern Aesthetics’ mission is to deliver actionable, expert-driven content covering injectables, surgery, energy-based devices, skin care, regenerative medicine, and practice development. Fulfilling that mission involves changing along with evolving reader preferences and broader industr
- Ultrasound Elastography Tracks Reversible Masseter Remodeling After BoNT-A Injectionshttps://modernaesthetics.com/news/ultrasound-elastography-tracks-reversible-masseter-remodeling-after-bont-a-injections/2484690/Botulinum neurotoxin type A (BoNT-A) induces reversible changes in both masseter volume and elasticity, according to a new prospective study using ultrasound elastography (USE) to quantify structural adaptation post-injection. The findings, published ahead of print
- Lumenis Debuts Stellar M22™ with XPL™ at ASDS 2025, Showcases Single-Session Clearance Datahttps://modernaesthetics.com/news/lumenis-debuts-stellar-m22-with-xpl-at-asds-2025-showcases-single-session-clearance-data/2484554/Lumenis Be. Ltd. introduced the next-generation Stellar M22™ with XPL™ Technology during the 2025 Annual American Society for Dermatologic Surgery (ASDS) Meeting, highlighting single-session clearance rates of up to 100% for vascular and pigmented lesions. The multi-application aesthetic platform